Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The Centers for Disease Control and Prevention released plans for the distribution of coronavirus vaccines. The logistical challenges could be as daunting as the scientific ones.
-
To reassure the public, nine companies issued a joint statement Tuesday saying they won't seek government approval for their coronavirus vaccines until full safety and effectiveness data are in hand.
-
The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?
-
Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower.
-
This is the sixth vaccine candidate to join Operation Warp Speed's portfolio, and the largest vaccine deal to date.
-
The president says the actions will lower drug prices, but policy experts say they will likely offer patients only minimal relief and may take months to implement, if they're implemented at all.
-
If the company's vaccine candidate pans out, Americans can receive it for free under the deal. The arrangement is part of the U.S. government's push to have a vaccine widely available by January.
-
Companies that made hats, socks and teddy bears have started producing surgical masks to protect people from COVID-19. Some sellers exaggerate their standing with the Food and Drug Administration.
-
An experimental COVID-19 medicine that has been shown to shorten the time people with severe illness have to stay in the hospital finally has a price tag that's lower than some analysts expected.
-
Gilead Sciences is donating its initial supply of the experimental treatment for COVID-19. The federal government is deciding where the scarce medicine goes, and there are questions about the choices.